Cell therapy for relapsing nervous system autoimmune diseases
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Genetic & congenital, Immune system & allergy clinical trials.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old and have one of these antibody-related nervous system autoimmune diseases: NMOSD, myasthenia gravis, CIDP, inflammatory muscle disease (IIM), multiple sclerosis types, autoimmune encephalitis, MOGAD, or POEMS/RMS.
- Your disease is “relapsing” or “not controlled” despite prior treatment (for example, long-term immunosuppressant use with ongoing symptoms, or recent relapses, or evidence of active disease).
- You’ve had blood and organ tests that are high enough (including white blood cell and platelet counts, adequate kidney function, and liver tests not too elevated).
- Your resting oxygen level is above 91%, and heart ultrasound shows good pumping function (LVEF 50% or higher).
- You can provide written consent and are expected to live at least 12 weeks; if you can become pregnant or impregnate someone, you must use reliable contraception for 1 year after treatment.
- You must be able to provide enough immune cells for making the CAR-T product (there must be adequate cells collected for manufacturing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This study tests a new treatment called CTX112, which uses modified immune cells to target and calm the immune system. It is for people with certain autoimmune diseases that have not responded to other treatments.
This trial tests a new immune-cell therapy (CAR-T) for people with certain autoimmune diseases of the brain and spinal cord that have not improved with standard treatments. The therapy aims to reset the immune system to stop it from attacking the nervous system.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.